ArticleNeurosurgical review2026
The outcome of microvascular decompression for hemifacial spasm associated with vertebral artery: A retrospective comparative study.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrovascular decompression (MVD) is an established treatment for hemifacial spasm (HFS). However, when the vertebral artery (VA) is the offending vessel (OV), the procedure is technically more challenging. Whether MVD yields comparable safety and efficacy in VA-associated versus non-VA-associated cases remains unclear and warrants further investigation. MATERIALS AND
methodsWe conducted a retrospective analysis of HFS patients treated at our study between September 2023 to February 2024. We enrolled 51 patients with HFS assigned to the two groups in accordance with the OVs.
resultsA total of 51 patients with HFS were divided into the VA-associated (n = 11) and non-VA-associated (n = 40) groups. Spasm-free relief (Park YS grades "excellent" or "good") was achieved in 81.8% and 82.5% of patients in the VA and non-VA groups, respectively (p = 0.694). Early remission occurred in 45.5% of VA cases and 52.5% of non-VA cases (p = 0.904). Transient postoperative complications, including vertigo, tinnitus, hearing loss, or facial paralysis, were noted in 7 VA-associated (63.6%) and 10 non-VA-associated (25.0%) patients (p < 0.05). Mean operative times were 147 ± 20.0 min in VA group) and 131.0 ± 30.0 min in non-VA group(p < 0.05) s. No major complications were observed in either group.
conclusionMVD is effective and safe for both VA- and non-VA-associated HFS. Although VA-associated cases involve greater surgical complexity and a higher incidence of transient postoperative symptoms, long-term outcomes remain comparable when adequate decompression is achieved.
Indexed as
Identifiers
42149222What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.